Lymph node assessment in melanoma

Journal of Surgical Oncology

Volumn 99, Issue 4, 2009, Pages 176-185

  Easson, Alexandra M ^a,b,c   Rotstein, Lorne E ^a,c,d   McCready, David R ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Lymph nodes; Melanoma; Sentinel lymph nodes; Surgery

Indexed keywords

ALPHA INTERFERON;

AXILLARY LYMPH NODE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIAGNOSTIC ERROR; ELECTIVE LYMPH NODE DISSECTION; HEAD AND NECK CANCER; HUMAN; INGUINAL LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE;

AXILLA; CHEMOTHERAPY, ADJUVANT; HEAD AND NECK NEOPLASMS; HUMANS; INGUINAL CANAL; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; NECK DISSECTION; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 62749141530     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21202     Document Type: Review

References (86)

1. Chao C, Martin RC, Ross MI, et al.: Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004;11:259-264.
2. McCune WS, Letterman GS: Malignant melanoma; ten-year results following excision and regional gland resection. Ann Surg 1955;141:901-909.
3. Veronesi U, Adamus J, Bandiera DC, et al.: Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977;297:627-630.
4. Veronesi U, Adamus J, Bandiera DC, et al.: Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-2430.
5. Sim FH, Taylor WF, Pritchard DJ, et al.: Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study. Mayo Clin Proc 1986;61:697-705.
6. Balch CM, Soong SJ, Bartolucci AA, et al.: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-263.
7. Balch CM, Soong S, Ross MI, et al.: Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000;7:87-97.
8. Cascinelli N, Morabito A, Santinami M, et al.: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. Lancet 1998;351:793-796.
9. Hochwald SN, Coit DG: Role of elective lymph node dissection in melanoma. Semin Surg Oncol 1998;14:276-282.
10. Cascinelli N: The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes. Eur J Surg Oncol 1996;22:123-127.
11. Balch CM: Surgical management of melanoma: Results of prospective randomized trials. Ann Surg Oncol 1998;5:301-309.
12. Gervasoni JE, Jr., Sbayi S, Cady B: Role of lymphadenectomy in surgical treatment of solid tumors: An update on the clinical data. Ann Surg Oncol 2007;14:2443-2462.
13. Balch CM: Melanoma. In Greene FL, Page DL, Fleming ID, et al. (eds): AJCC Cancer Staging Manual. Philadelphia, PA: Lippincott Raven Publishers, 2002, pp 209-217.
14. Balch CM, Soong SJ, Gershenwald JE, et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
15. McMasters K, Wong SL, Edwards MJ, et al.: Factors that predict the presence of sentinel lymph node metastases in patients with melanoma. Surgery 2001;130:151-156.
16. Karakousis CP: Therapeutic node dissections in malignant melanoma. Ann Surg Oncol 1998;5:473-482.
17. Cabanas RM: An approach for the treatment of penile carcinoma. Cancer 1977;39:456-466.
18. Morton DL, Wen DR, Wong JH, et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
19. Morton DL, Cochran AJ, Thompson JF, et al.: Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-311.
20. McMasters KM, Noyes RD, Reintgen DS, et al.: Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004;86:212-223.
21. Reintgen D, Pendas S, Jakub J, et al.: National trials involving lymphatic mapping for melanoma: The Multicenter Selective Lymphadenectomy Trial, the Sunbelt Melanoma Trial, and the Florida Melanoma Trial. Semin Oncol 2004;31:363-373.
22. Morton DL, Thompson JF, Cochran AJ, et al.: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-1317.
23. Gershenwald JE, Thompson W, Mansfield PF, et al.: Multiinstitutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983.
24. Wagner JD, Gordon MS, Chuang TY, et al.: Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000;89:453-462.
25. Statius Muller MG, van Leeuwen PA, van Diest PJ, et al.: Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World J Surg 2002;26:1405-1411.
26. Thomas JM, Clark MA: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 2004;30:686-691.
27. Kretschmer L, Beckmann I, Thoms KM, et al.: Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. Eur J Cancer 2005;41:531-538.
28. Kang JC, Wanek LA, Essner R, et al.: Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 2005;23:4764-4770.
29. Pawlik TM, Ross MI, Thompson JF, et al.: The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 2005;23:4588-4590.
30. van Poll D, Thompson JF, Colman MH, et al.: A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:597-608.
31. Kanzler MH, Levitt L, Lin A: Sentinel-node biopsy in melanoma. N Engl J Med 2007;356:419-421.
32. Thomas JM: Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 2008;5:18-23.
33. Gonzalez U: Cloud over sentinel node biopsy: Unlikely survival benefit in melanoma. Arch Dermatol 2007;143:775-776.
34. Cochran AJ, Wen DR, Huang RR, et al.: Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 2004;17:747-755.
35. Govindarajan A, Ghazarian DM, McCready DR, et al.: Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol 2007;14:906-912.
36. Scolyer RA, Li LX, McCarthy SW, et al.: Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol 2004;122:532-539.
37. Dewar DJ, Newell B, Green MA, et al.: The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 2004;22:3345-3349.
38. Murray CA, Leong WL, McCready DR, et al.: Histopathological patterns of melanoma metastases in sentinel lymph nodes. J Clin Pathol 2004;57:64-67.
39. Sabel MS, Griffith K, Sondak VK, et al.: Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 2005;201:37-47.
40. McMasters KM, Wong SL, Edwards MJ, et al.: Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 2002;9:137-141.
41. Lee JH, Essner R, Torisu-Itakura H, et al.: Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 2004;22:3677-3684.
42. Wong SL, Morton DL, Thompson JF, et al.: Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: A multi-institutional study. Ann Surg Oncol 2006;13:809-816.
43. Verma S, Quirt I, McCready D, et al.: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:1431-1442.
44. Anaya DA, Xing Y, Feng L, et al.: Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 2008.
45. Shah GD, Chapman PB: Adjuvant therapy of melanoma. Cancer J 2007;13:217-222.
46. Emery RE, Stevens JS, Nance RW, et al.: Sentinel node staging of primary melanoma by the "10% rule": Pathology and clinical outcomes. Am J Surg 2007;193:618-622.
47. Kroon HM, Lowe L, Wong S, et al.: What is a sentinel node? Reevaluating the 10% rule for sentinel lymph node biopsy in melanoma. J Surg Oncol 2007;95:623-628.
48. Pijpers R, Borgstein PJ, Meijer S, et al.: Transport and retention of colloidal tracers in regional lymphoscintigraphy in melanoma: Influence on lymphatic mapping and sentinel node biopsy. Melanoma Res 1998;8:413-418.
49. Leong WL, Ghazarian DM, McCready DR: Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity. J Surg Oncol 2003;82:143-146.
50. Ariyan S, li-Salaam P, Cheng DW, et al.: Reliability of lymphatic mapping after wide local excision of cutaneous melanoma. Ann Surg Oncol 2007;14:2377-2383.
51. Gannon CJ, Rousseau DL, Jr., Ross MI, et al.: Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer 2006;107:2647-2652.
52. McHugh JB, Su L, Griffith KA, et al.: Significance of multiple lymphatic basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol 2006;13:1216-1223.
53. McMasters KM, Chao C, Wong SL, et al.: Interval sentinel lymph nodes in melanoma. Arch Surg 2002;137:543-547.
54. Matter M, Nicod LM, Allaoua M, et al.: The role of interval nodes in sentinel lymph node mapping and dissection for melanoma patients. J Nucl Med 2007;48:1607-1613.
55. Carling T, Pan D, Ariyan S, et al.: Diagnosis and treatment of interval sentinel lymph nodes in patients with cutaneous melanoma. Plast Reconstr Surg 2007;119:907-913.
56. Bryan J, Nieweg OE: New boundaries for lymphatic mapping-report of the Fifth International Sentinel Node Conference. Melanoma Res 2007;17:261-263.
57. Scolyer RA, Thompson JF, McCarthy SW, et al.: Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. J Am Coll Surg 2005;201:821-823.
58. Stojadinovic A, Allen PJ, Clary BM, et al.: Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg 2002;235:92-98.
59. Edgerton ME, Roberts SA, Montone KT: Immunohistochemical performance of antibodies on previously frozen tissue. Appl Immunohistochem Mol Morphol 2000;8:244-248.
60. Soo V, Shen P, Pichardo R, et al.: Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology. Ann Surg Oncol 2007;14:1612-1617.
61. Spanknebel K, Coit DG, Bieligk SC, et al.: Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: Recommendations for standardizing pathologic analysis. Am J Surg Pathol 2005;29:305-317.
62. Karimipour DJ, Lowe L, Su L, et al.: Standard immunostains for melanoma in sentinel lymph node specimens: Which ones are most useful? J Am Acad Dermatol 2004;50:759-764.
63. Anbari KK, Schuchter LM, Bucky LP, et al.: Melanoma of unknown primary site: Presentation, treatment, and prognosis - A single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer 1997;79:1816-1821.
64. Vijuk G, Coates AS: Survival of patients with visceral metastatic melanoma from an occult primary lesion: A retrospective matched cohort study. Ann Oncol 1998;9:419-422.
65. Schlagenhauff B, Stroebel W, Ellwanger U, et al.: Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: Recommendations for initial staging examinations. Cancer 1997;80:60-65.
66. Cormier JN, Xing Y, Feng L, et al.: Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006;106:2012-2020.
67. Lee CC, Faries MB, Wanek LA, et al.: Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008;26:535-541.
68. Young SE, Martinez SR, Faries MB, et al.: Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes? Cancer J 2006;12:207-211.
69. Badgwell B, Xing Y, Gershenwald JE, et al.: Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol 2007;14:2867-2875.
70. Galliot-Repkat C, Cailliod R, Trost O, et al.: The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma. Eur J Surg Oncol 2006;32:790-794.
71. Calabro A, Singletary SE, Balch CM: Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989;124:1051-1055.
72. van Akkooi AC, Bouwhuis MG, van Geel AN, et al.: Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 2007;33:102-108.
73. Lee RJ, Gibbs JF, Proulx GM, et al.: Nodal basin recurrence following lymph node dissection for melanoma: Implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000;46:467-474.
74. Balch CM, Ross MI: Melanoma patients with iliac nodal metastases can be cured. Ann Surg Oncol 1999;6:230-231.
75. Pidhorecky I, Lee RJ, Proulx G, et al.: Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol 2001;8:109-115.
76. Warso MA, Das Gupta TK: Melanoma recurrence in a previously dissected lymph node basin. Arch Surg 1994;129:252-255.
77. Petrasek AJ, Semple JL, McCready DR: The surgical and oncologic significance of the axillary arch during axillary lymphadenectomy. Can J Surg 1997;40:44-47.
78. Reintgen D, Cruse CW, Wells K, et al.: The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-767.
79. Thompson JF, McCarthy WH, Bosch CM, et al.: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-260.
80. Krag DN, Meijer SJ, Weaver DL, et al.: Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-658.
81. Albertini JJ, Cruse CW, Rapaport D, et al.: Intraoperative radiolympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217-224.
82. Karakousis CP, Velez AF, Spellman JE, Jr., et al.: The technique of sentinel node biopsy. Eur J Surg Oncol 1996;22:271-275.
83. Mudun A, Murray DR, Herda SC, et al.: Early stage melanoma: Lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. Radiology 1996;199:171-175.
84. Kapteijn BA, Nieweg OE, Liem I, et al.: Localizing the sentinel node in cutaneous melanoma: Gamma probe detection versus blue dye. Ann Surg Oncol 1997;4:156-160.
85. Leong SP, Steinmetz I, Habib FA, et al.: Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997;132:666-672.
86. Bostick P, Essner R, Glass E, et al.: Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999;134:43-49.